A Case Study of Personalized Medicine
- 4 April 2008
- journal article
- policy forum
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 320 (5872), 53-54
- https://doi.org/10.1126/science.1156604
Abstract
Marketing of unproven tests shows the need for regulatory action to protect public health.This publication has 8 references indexed in Scilit:
- Pharmacogenomics — Ready for Prime Time?The New England Journal of Medicine, 2008
- Letting the Genome out of the Bottle — Will We Get Our Wish?The New England Journal of Medicine, 2008
- Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitorsGenetics in Medicine, 2007
- ASHG Statement* on Direct-to-Consumer Genetic Testing in the United StatesAmerican Journal of Human Genetics, 2007
- Genetic Testing OversightScience, 2006
- Direct-to-consumer genetic testing: Access and marketingGenetics in Medicine, 2004
- Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variantsPharmacogenetics, 2004
- The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolismNature, 2000